ப்ரிடிக்ஶந் அமைப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Evive Awarded Patent for Healthcare Recommendation and Prediction System

Evive Awarded Patent for Healthcare Recommendation and Prediction System
prweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prweb.com Daily Mail and Mail on Sunday newspapers.

United statesPrashant srivastavaTrademark officeHealthcare recommendationPrediction systemUnited states patentCoverage final ruleAppropriations actஒன்றுபட்டது மாநிலங்களில்பிரஷண்ட் சிரிவாஸ்தவமுத்திரை அலுவலகம்ப்ரிடிக்ஶந் அமைப்புஒன்றுபட்டது மாநிலங்களில் காப்புரிமைபாதுகாப்பு இறுதி ஆட்சி

First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene s Innovative Individualized Immunotherapy

First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene s Innovative Individualized Immunotherapy
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesFrance generalJean pierre delordCheshire merseysideMaud brandelyChristian ottensmeierAlexandra martinezChristophe le tourneauTransgene euronextYujie zhaoInstitut curieHead of the department drug developmentClatterbridge cancer centreLiverpool cancer research instituteUniversity of liverpool

Thunderbird: the turtle that was captured twice by fishing gears

Thunderbird: the turtle that was captured twice by fishing gears
ub.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ub.edu Daily Mail and Mail on Sunday newspapers.

Canary islandsSpain generalUnited statesCape verdeComunidad autonoma de catalunaMiquel gomilaJacob gonzDavid marchEnvironmental sciencesAtmospheric administration of the united statesNational service of marine fishingUniversity of barcelonaBirdlife internationalCentre for ecologyNational oceanicPalma aquarium foundation

First Head & Neck Cancer Patient Treated in France in a Phase I Trial With TG4050 (myvac® Platform), Transgene s Innovative Individualized Immunotherapy

(Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that a first patient with head and neck cancer has been dosed with the Company’s innovative individualized immunotherapy, TG4050. This novel therapeutic vaccine is based on Transgene’s myvac® technology platform, which leverages cutting-edge Artificial Intelligence (AI) capabilities to customize the treatment for each patient. This innovative approach combines Transgene’s expertise in virus-based immunotherapies, NEC’s longstanding AI technologies and the commitment of prestigious cancer care centers. THE FIRST PATIENT HAS BEEN DOSED AT THE IUCT ONCOPOLE IN TOULOUSE, France,

United statesFrance generalUnited kingdomAlexandra martinezChristian ottensmeierChristophe le tourneauJean pierre delordTransgene euronextInstitut curieInstitut claudius regaudHead of the department drug developmentClaudius regaud instituteClatterbridge cancer centreUniversity of liverpoolHealth campusToulouse cancer research center

First Head & Neck Cancer Patient Treated in France in a Phase I Trial With TG4050 (myvac Platform), Transgenes Innovative Individualized Immunotherapy

Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that a first patient with head and neck cancer has been dosed with the Company’s innovative individualized immunotherapy, TG4050. This novel therapeutic vaccine is based on Transgene’s myvac® technology platform, which leverages cutting-edge Artificial Intelligence (AI) capabilities to customize the treatment for each patient. This innovative approach combines Transgene’s expertise in virus-based immunotherapies, NEC’s longstanding AI technologies and the commitment of prestigious cancer care centers. THE FIRST PATIENT HAS BEEN DOSED AT THE IUCT ONCOPOLE IN TOULOUSE, France,

United statesFrance generalUnited kingdomLucie larguierJean pierre delordSylvie berrebiInstitut claudius regaudAlexandra martinezChristian ottensmeierChristophe le tourneauTransgene euronextInstitut curieCitigate dewe rogersonHead of the department drug developmentClaudius regaud instituteClatterbridge cancer centre